KRAS and colorectal cancer: Mouse models of pancreatic and colorectal cancers driven by the Kras oncogene exhibit a weaker response to serine and glycine depletion, reflecting Kras activation, which upregulates enzymes in the serine synthesis pathway and promotes de novo serine synthesis (10).